Sera Prognostics Inc (SERA)

Currency in USD
1.79
-0.12(-6.28%)
Closed·
1.790.00(0.00%)
·
SERA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.701.85
52 wk Range
1.374.20
Key Statistics
Prev. Close
1.91
Open
1.8
Day's Range
1.7-1.85
52 wk Range
1.37-4.2
Volume
77.18K
Average Volume (3m)
60.03K
1-Year Change
-54.4529%
Book Value / Share
2.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SERA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.00
Upside
+179.33%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Sera Prognostics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc Earnings Call Summary for Q4/2025

  • Q4 2025 EPS of -$0.16 beat forecast of -$0.19 by 15.79%, but revenue of $10M missed estimates by 7.15%, falling 58.3% year-over-year
  • Stock declined 4.98% to $2.01 post-earnings; shares down 35% YTD and 53% over past year amid investor concerns over revenue performance
  • Net loss improved to $7.9M from $8.6M in Q4 2024; operating expenses decreased 4.3% YOY to $9M, demonstrating cost management progress
  • PRIME study publication provides clinical validation for PreTRM test; company focusing on converting payer discussions into contracts
  • 2026 guidance projects cash operating expenses in low $30M range, consistent with 2025; expansion of partner programs key to revenue growth
Last Updated: 18/03/2026, 21:40
Read Full Transcript

Compare SERA to Peers and Sector

Metrics to compare
SERA
Peers
Sector
Relationship
P/E Ratio
−2.2x−2.7x−0.5x
PEG Ratio
−0.09−0.100.00
Price/Book
0.9x2.7x2.6x
Price / LTM Sales
852.9x8.6x3.1x
Upside (Analyst Target)
161.8%68.6%55.6%
Fair Value Upside
Unlock14.2%8.6%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.00
(+179.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy5.00+179.33%-New Coverage15/12/2025

Earnings

Latest Release
18/03/2026
EPS / Forecast
-0.16 / -0.19
Revenue / Forecast
10K / 10.77K
EPS Revisions
Last 90 days

People Also Watch

1.93
HTLM
+0.52%
10.10
LIEN
+2.02%
6.75
ACCS
-2.46%
18.69
TRC
+2.41%
0.256
BRTX
+11.80%

FAQ

What Is the Sera Prognostics (SERA) Share Price Today?

The Sera Prognostics stock price today is 1.79 USD.

What Stock Exchange Does Sera Prognostics (SERA) Trade On?

Sera Prognostics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Sera Prognostics?

The stock symbol (also called a 'ticker') for Sera Prognostics is "SERA."

What Is the Current Sera Prognostics Market Cap?

As of today, Sera Prognostics market cap is 69.08M USD.

What Is Sera Prognostics's (SERA) Earnings Per Share (TTM)?

The Sera Prognostics EPS is currently -0.75 (Trailing Twelve Months).

When Is the Next Sera Prognostics Earnings Date?

Sera Prognostics's next earnings report will be released on 13/05/2026.

Is SERA a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sera Prognostics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sera Prognostics Stock Split?

Sera Prognostics has split 0 times. (See the SERA stock split history page for full effective split date and price information.)

How Many Employees Does Sera Prognostics Have?

Sera Prognostics has 64 employees.

What is the current trading status of Sera Prognostics (SERA)?

As of 20/03/2026, Sera Prognostics (SERA) is trading at a price of 1.79 USD, with a previous close of 1.91 USD. The stock has fluctuated within a day range of 1.70 USD to 1.85 USD, while its 52-week range spans from 1.37 USD to 4.20 USD.

What Is Sera Prognostics (SERA) Price Target According to Analysts?

The average 12-month price target for Sera Prognostics is 5.00 USD, with a high estimate of 5 USD and a low estimate of 5 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +179.33% Upside potential.

What Is the SERA Premarket Price?

SERA's last pre-market stock price is 1.79 USD. The pre-market share volume is 255.00, and the stock has decreased by -0.12, or -6.28%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.